553.48 USD
↗ 7.95 (1.46%)AT CLOSE (11:59 AM EDT)
Madrigal Pharmaceuticals, Inc. Common Stock
MDGLNASDAQ • USD
545.82
↘ 7.66 (1.38%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
545.82
↘ 7.66 (1.38%)
Market: CLOSED
Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) is currently trading at $553.31. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Jul 17, 2026.
Open?$538.85
High?$560.09
Low?$536.01
Prev. Close?$545.53
Volume?528.3K
Avg. Volume?375.2K
VWAP?$549.43
Rel. Volume?1.41x
Bid / Ask
Bid?$506.54 × 40
Ask?$585.26 × 40
Spread?$78.72
Midpoint?$545.90
Valuation & Ratios
Market Cap?12.6B
Shares Out?23.1M
Float?16.5M
Float %?71.7%
P/E Ratio?N/A
P/B Ratio?23.14
EPS?-$13.42
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Employees
915
Market Cap
12.6B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2007-02-06
Address
200 BARR HARBOR DRIVE, SUITE 400
WEST CONSHOHOCKEN, PA 19428
Phone: 404-380-9263
WEST CONSHOHOCKEN, PA 19428
Phone: 404-380-9263
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?100
Momentum?73
Short Sent.?50
Piotroski F-Score?1/9Weak
Altman Z-Score?9.44Safe
Confidence?58%Low
Short InterestSqueeze Risk
Short % of Float?21.33%Squeeze Risk
Short Interest?3.5M
Days to Cover?6.2
Free Float16.5M
Avg Daily Volume568.8K
Settlement Date2026-06-30
Financial Health
Current Ratio?3.48Strong
Quick Ratio?3.15Strong
Cash Ratio?0.67Adequate
Debt/Equity?0.63Moderate
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score50/100
P/E?N/A▾
P/B?23.14HIGH▾
Peers100
S&P3
P/S?11.11HIGH▾
Peers100
S&P7
P/FCF?N/A▾
EV/EBITDA?-40.7CHEAP▾
S&P97
EV/Sales?11.21HIGH▾
Peers100
S&P9
Returns & Efficiency
ROE?-56.9%WEAK▾
S&P3
ROA?-25.2%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-272413000
Enterprise Value?$12.7B
Fundamentals ratios updated end of day